259 related articles for article (PubMed ID: 31284853)
1. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
2. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of
Prates JLB; Lopes JR; Chin CM; Ferreira EI; Dos Santos JL; Scarim CB
Curr Med Chem; 2024; 31(16):2285-2308. PubMed ID: 37888814
[TBL] [Abstract][Full Text] [Related]
4. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
5. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
[TBL] [Abstract][Full Text] [Related]
6. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
7. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
8. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
[TBL] [Abstract][Full Text] [Related]
9. Infectious diseases. Drug developers finally take aim at a neglected disease.
Leslie M
Science; 2011 Aug; 333(6045):933-5. PubMed ID: 21852468
[No Abstract] [Full Text] [Related]
10. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
12. High throughput screening for anti-Trypanosoma cruzi drug discovery.
Alonso-Padilla J; Rodríguez A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
[TBL] [Abstract][Full Text] [Related]
13. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
14. Lead identification to clinical candidate selection: drugs for Chagas disease.
Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Strong 3-Nitro-2-Phenyl-
Carey SM; O'Neill DM; Conner GB; Sherman J; Rodriguez A; D'Antonio EL
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673904
[TBL] [Abstract][Full Text] [Related]
16. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic screening approaches for Chagas disease drug discovery.
Chatelain E; Ioset JR
Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
[TBL] [Abstract][Full Text] [Related]
18. Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes.
Salas-Sarduy E; Landaburu LU; Karpiak J; Madauss KP; Cazzulo JJ; Agüero F; Alvarez VE
Sci Rep; 2017 Sep; 7(1):12073. PubMed ID: 28935948
[TBL] [Abstract][Full Text] [Related]
19. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
Sbaraglini ML; Bellera CL; Fraccaroli L; Larocca L; Carrillo C; Talevi A; Alba Soto CD
Int J Antimicrob Agents; 2016 Jul; 48(1):91-95. PubMed ID: 27216381
[TBL] [Abstract][Full Text] [Related]
20. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
